Marginal transfer of ReoPro™ (Abciximab) compared with immunoglobulin G (F105), inulin and water in the perfused human placenta in vitro

  • Miller R
  • Mace K
  • Polliotti B
 et al. 
  • 12


    Mendeley users who have this article in their library.
  • 39


    Citations of this article.


ReoPro™ (Abciximab), a Fab fragment of a human-murine chimeric monoclonal antibody, binds to glycoprotein IIb/IIIa receptors on human platelets and inhibits platelet aggregation. Can ReoPro transit the human placenta since it does not have an Fc (domain) as does IgG? This question was addressed using an in vitro term human placental lobular dual perfusion model. ReoPro, along with 3H2O, inulin or125I-F105 human IgG1, were added to the maternal reservoir for 6 or >12 h, ReoPro was equivalent to, or exceeded, clinically relevant plasma concentrations (0.3-3 μg/ml).3H2O rapidly appeared in the fetal circuit, while fetal14C-inulin never equilibrated with the maternal inulin. After 6 h,125I-F105 was present with fetal/maternal percentages - 0.55 per cent. ReoPro was not detectable (

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text


  • Richard K. Miller

  • K. Mace

  • B. Polliotti

  • R. DeRita

  • W. Hall

  • G. Treacy

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free